US proposes curbs on investment in Chinese biotech firms
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓The US Treasury Department on Thursday proposed new limits on American investment in Chinese biotechnology firms over national security concerns.
- ✓These rules could restrict equity deals and joint ventures.
- ✓Analyst Duane Wright said, "This is still the opening stage of the rule-making, so the scope could change before finalization."
Story at a Glance
- Category
- BUSINESS
- Reported By
- MoneyControl
- Reading Speed
- 3 Minute(s)
- Market Focus
- India Economy
The Trump administration is seeking to restrict American investment in Chinese biotechnology companies, potentially complicating financial ties at a time when US drugmakers are increasingly turning to China for new medicines. The Treasury Department on Thursday proposed adding biotechnology to a list of sensitive technologies subject to investment limits involving foreign adversaries, citing national security concerns. The proposed regulations would require American investors to notify the government about certain transactions involving foreign companies developing sensitive technologies and prohibit others entirely.
The rules would expand an existing program targeting investments in areas including artificial intelligence, semiconductors and quantum computing. The move represents the latest escalation in Washington's efforts to rein in China's biotech advances.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
MoneyControl
Read the full, original unfiltered story directly on the publisher's portal.